Impact of a dual glucose-dependent insulinotropic peptide/glucagon-like peptide-1 receptor agonist tirzepatide on heart rate among patients with type 2 diabetes: A systematic review and pairwise and network meta-analysis.

Yang Y, He L, Liu P, Wang J, Yang N, Li Z, Ping F, Xu L, Li W, Zhang H, Li Y

Diabetes, obesity & metabolism20 Oct 2023Cited by 11 (Europe PMC)

PMID37860884DOI10.1111/dom.15342PepBankPUB-37860884

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study11

11 results from studies that gave the peptide. 11 results from people.

01HumanSystematic reviewEfficacy outcome
In adults with type 2 diabetes, tirzepatide raised heart rate more than the combined control group in a pairwise meta-analysis.
In plain wordsIn adults with type 2 diabetes, heart rate rose more with tirzepatide than with the combined control treatments.
Peptide
Tirzepatide
Outcome
IncreaseHeart rate, tirzepatide versus combined control
Study
n: not reported in source
Comparator
Combined control group (GLP-1 receptor agonists and non-GLP-1 receptor agonists)
Outcome group
Heart function · Cardiovascular
Studied dose
5, 10 and 15 mgAs given in this study (human).
Measurements
Mean difference in heart rate
1.82 beats per minute
tirzepatide vs combined control
Source sentences
Summary
Pairwise meta-analysis showed that, compared with combined the control group, there were significantly greater increases in heart rates in the TZP group (MD 1.82, 95% confidence interval [CI] 0.75, 2.89).
2 context sentences(design, population, supporting numbers)
Summary · context
Randomized controlled trials (RCTs) comparing TZP at doses of 5, 10 and 15 mg in adults with type 2 diabetes were included.
Summary · context
Eight articles were included in this systematic review and meta-analysis.
Report a problemFND-3786088401
02HumanSystematic reviewEfficacy outcome
In adults with type 2 diabetes, tirzepatide raised heart rate more than GLP-1 receptor agonists in a pairwise meta-analysis.
In plain wordsIn adults with type 2 diabetes, heart rate rose more with tirzepatide than with GLP-1 receptor agonists.
Peptide
Tirzepatide
Outcome
IncreaseHeart rate, tirzepatide versus GLP-1 receptor agonists
Study
n: not reported in source
Comparator
GLP-1 receptor agonists
Outcome group
Heart function · Cardiovascular
Studied dose
5, 10 and 15 mgAs given in this study (human).
Measurements
Mean difference in heart rate
2.29 beats per minute
tirzepatide vs GLP-1 RAs
Source sentences
Summary
Similar significant rises were identified when comparing TZP with GLP-1RAs and non-GLP-1RAs (GLP-1 RAs: MD 2.29, 95% CI 1.00, 3.59; non-GLP-1RAs: MD 1.58, 95% CI 0.26, 2.91).
2 context sentences(design, population, supporting numbers)
Summary · context
Randomized controlled trials (RCTs) comparing TZP at doses of 5, 10 and 15 mg in adults with type 2 diabetes were included.
Summary · context
Eight articles were included in this systematic review and meta-analysis.
Report a problemFND-3786088402
03HumanSystematic reviewEfficacy outcome
In adults with type 2 diabetes, tirzepatide raised heart rate more than non-GLP-1 receptor agonist comparators in a pairwise meta-analysis.
In plain wordsIn adults with type 2 diabetes, heart rate rose more with tirzepatide than with comparators that were not GLP-1 receptor agonists.
Peptide
Tirzepatide
Outcome
IncreaseHeart rate, tirzepatide versus non-GLP-1 receptor agonists
Study
n: not reported in source
Comparator
Non-GLP-1 receptor agonists
Outcome group
Heart function · Cardiovascular
Studied dose
5, 10 and 15 mgAs given in this study (human).
Measurements
Mean difference in heart rate
1.58 beats per minute
tirzepatide vs non-GLP-1 RAs
Source sentences
Summary
Similar significant rises were identified when comparing TZP with GLP-1RAs and non-GLP-1RAs (GLP-1 RAs: MD 2.29, 95% CI 1.00, 3.59; non-GLP-1RAs: MD 1.58, 95% CI 0.26, 2.91).
2 context sentences(design, population, supporting numbers)
Summary · context
Randomized controlled trials (RCTs) comparing TZP at doses of 5, 10 and 15 mg in adults with type 2 diabetes were included.
Summary · context
Eight articles were included in this systematic review and meta-analysis.
Report a problemFND-3786088403
04HumanSystematic reviewEfficacy outcome
In adults with type 2 diabetes, tirzepatide 5 mg was associated with a smaller heart rate increase than tirzepatide 10 mg in a pairwise meta-analysis.
In plain wordsIn adults with type 2 diabetes, heart rate rose less with tirzepatide 5 mg than with 10 mg.
Peptide
Tirzepatide
Outcome
DecreaseHeart rate, tirzepatide 5 mg versus 10 mg
Study
n: not reported in source
Comparator
Tirzepatide 10 mg
Outcome group
Heart function · Cardiovascular
Studied dose
5 mgAs given in this study (human).
Measurements
Mean difference in heart rate
−0.97 beats per minute
5 mg vs 10 mg
Source sentences
Summary
TZP 5 mg was associated with smaller increases in heart rates compared to TZP 10 mg and TZP 15 mg (TZP 10 mg: MD -0.97, 95% CI -1.79, -0.14; TZP 15 mg: MD -2.57, 95% CI -3.79, -1.35).
2 context sentences(design, population, supporting numbers)
Summary · context
Randomized controlled trials (RCTs) comparing TZP at doses of 5, 10 and 15 mg in adults with type 2 diabetes were included.
Summary · context
Eight articles were included in this systematic review and meta-analysis.
Report a problemFND-3786088404
05HumanSystematic reviewEfficacy outcome
In adults with type 2 diabetes, tirzepatide 5 mg was associated with a smaller heart rate increase than tirzepatide 15 mg in a pairwise meta-analysis.
In plain wordsIn adults with type 2 diabetes, heart rate rose less with tirzepatide 5 mg than with 15 mg.
Peptide
Tirzepatide
Outcome
DecreaseHeart rate, tirzepatide 5 mg versus 15 mg
Study
n: not reported in source
Comparator
Tirzepatide 15 mg
Outcome group
Heart function · Cardiovascular
Studied dose
5 mgAs given in this study (human).
Measurements
Mean difference in heart rate
−2.57 beats per minute
5 mg vs 15 mg
Source sentences
Summary
TZP 5 mg was associated with smaller increases in heart rates compared to TZP 10 mg and TZP 15 mg (TZP 10 mg: MD -0.97, 95% CI -1.79, -0.14; TZP 15 mg: MD -2.57, 95% CI -3.79, -1.35).
2 context sentences(design, population, supporting numbers)
Summary · context
Randomized controlled trials (RCTs) comparing TZP at doses of 5, 10 and 15 mg in adults with type 2 diabetes were included.
Summary · context
Eight articles were included in this systematic review and meta-analysis.
Report a problemFND-3786088405
06HumanSystematic reviewEfficacy outcome
In adults with type 2 diabetes, tirzepatide 10 mg increased heart rate less than tirzepatide 15 mg in a pairwise meta-analysis.
In plain wordsIn adults with type 2 diabetes, heart rate rose less with tirzepatide 10 mg than with 15 mg.
Peptide
Tirzepatide
Outcome
DecreaseHeart rate, tirzepatide 10 mg versus 15 mg
Study
n: not reported in source
Comparator
Tirzepatide 15 mg
Outcome group
Heart function · Cardiovascular
Studied dose
10 mgAs given in this study (human).
Measurements
Mean difference in heart rate
−1.5 beats per minute
10 mg vs 15 mg
Source sentences
Summary
TZP 10 mg increased heart rate less than TZP 15 mg (MD -1.5, 95% CI -2.38, -0.82).
2 context sentences(design, population, supporting numbers)
Summary · context
Randomized controlled trials (RCTs) comparing TZP at doses of 5, 10 and 15 mg in adults with type 2 diabetes were included.
Summary · context
Eight articles were included in this systematic review and meta-analysis.
Report a problemFND-3786088406
07HumanSystematic reviewEfficacy outcome
In adults with type 2 diabetes, a network meta-analysis found tirzepatide 15 mg raised heart rate more than tirzepatide 5 mg.
In plain wordsIn adults with type 2 diabetes, heart rate rose more with tirzepatide 15 mg than with 5 mg.
Peptide
Tirzepatide
Outcome
IncreaseHeart rate, tirzepatide 15 mg versus 5 mg (network meta-analysis)
Study
n: not reported in source
Comparator
Tirzepatide 5 mg
Outcome group
Heart function · Cardiovascular
Studied dose
15 mgAs given in this study (human).
Measurements
Mean difference in heart rate
2.53 beats per minute
15 mg vs 5 mg
Source sentences
Summary
Network meta-analysis indicated that TZP 15 mg was associated with significant increases in heart rate compared with TZP 5 mg (MD 2.53, 95% CI 1.43, 3.62)
2 context sentences(design, population, supporting numbers)
Summary · context
Randomized controlled trials (RCTs) comparing TZP at doses of 5, 10 and 15 mg in adults with type 2 diabetes were included.
Summary · context
Eight articles were included in this systematic review and meta-analysis.
Report a problemFND-3786088407
08HumanSystematic reviewEfficacy outcome
In adults with type 2 diabetes, a network meta-analysis found tirzepatide 15 mg raised heart rate more than tirzepatide 10 mg.
In plain wordsIn adults with type 2 diabetes, heart rate rose more with tirzepatide 15 mg than with 10 mg.
Peptide
Tirzepatide
Outcome
IncreaseHeart rate, tirzepatide 15 mg versus 10 mg (network meta-analysis)
Study
n: not reported in source
Comparator
Tirzepatide 10 mg
Outcome group
Heart function · Cardiovascular
Studied dose
15 mgAs given in this study (human).
Measurements
Mean difference in heart rate
1.44 beats per minute
15 mg vs 10 mg
Source sentences
Summary
Network meta-analysis indicated that TZP 15 mg was associated with significant increases in heart rate
3 context sentences(design, population, supporting numbers)
Summary · context
TZP 10 mg (MD 1.44, 95% CI 0.35, 2.53)
Summary · context
Randomized controlled trials (RCTs) comparing TZP at doses of 5, 10 and 15 mg in adults with type 2 diabetes were included.
Summary · context
Eight articles were included in this systematic review and meta-analysis.
Report a problemFND-3786088408
09HumanSystematic reviewEfficacy outcome
In adults with type 2 diabetes, a network meta-analysis found tirzepatide 15 mg raised heart rate more than GLP-1 receptor agonists.
In plain wordsIn adults with type 2 diabetes, heart rate rose more with tirzepatide 15 mg than with GLP-1 receptor agonists.
Peptide
Tirzepatide
Outcome
IncreaseHeart rate, tirzepatide 15 mg versus GLP-1 receptor agonists (network meta-analysis)
Study
n: not reported in source
Comparator
GLP-1 receptor agonists
Outcome group
Heart function · Cardiovascular
Studied dose
15 mgAs given in this study (human).
Measurements
Mean difference in heart rate
3.46 beats per minute
15 mg vs GLP-1 RAs
Source sentences
Summary
Network meta-analysis indicated that TZP 15 mg was associated with significant increases in heart rate
3 context sentences(design, population, supporting numbers)
Summary · context
GLP-1RAs (MD 3.46, 95% CI 1.67, 5.25)
Summary · context
Randomized controlled trials (RCTs) comparing TZP at doses of 5, 10 and 15 mg in adults with type 2 diabetes were included.
Summary · context
Eight articles were included in this systematic review and meta-analysis.
Report a problemFND-3786088409
10HumanSystematic reviewEfficacy outcome
In adults with type 2 diabetes, a network meta-analysis found tirzepatide 15 mg raised heart rate more than insulin.
In plain wordsIn adults with type 2 diabetes, heart rate rose more with tirzepatide 15 mg than with insulin.
Peptide
Tirzepatide
Outcome
IncreaseHeart rate, tirzepatide 15 mg versus insulin (network meta-analysis)
Study
n: not reported in source
Comparator
Insulin
Outcome group
Heart function · Cardiovascular
Studied dose
15 mgAs given in this study (human).
Measurements
Mean difference in heart rate
2.86 beats per minute
15 mg vs insulin
Source sentences
Summary
Network meta-analysis indicated that TZP 15 mg was associated with significant increases in heart rate
3 context sentences(design, population, supporting numbers)
Summary · context
insulin (MD 2.86, 95% CI 1.32, 4.41)
Summary · context
Randomized controlled trials (RCTs) comparing TZP at doses of 5, 10 and 15 mg in adults with type 2 diabetes were included.
Summary · context
Eight articles were included in this systematic review and meta-analysis.
Report a problemFND-3786088410
11HumanSystematic reviewEfficacy outcome
In adults with type 2 diabetes, a network meta-analysis found tirzepatide 15 mg raised heart rate more than placebo.
In plain wordsIn adults with type 2 diabetes, heart rate rose more with tirzepatide 15 mg than with placebo.
Peptide
Tirzepatide
Outcome
IncreaseHeart rate, tirzepatide 15 mg versus placebo (network meta-analysis)
Study
n: not reported in source
Comparator
Placebo
Outcome group
Heart function · Cardiovascular
Studied dose
15 mgAs given in this study (human).
Measurements
Mean difference in heart rate
2.96 beats per minute
15 mg vs placebo
Source sentences
Summary
Network meta-analysis indicated that TZP 15 mg was associated with significant increases in heart rate
3 context sentences(design, population, supporting numbers)
Summary · context
placebo (MD 2.96, 95% CI 1.36, 4.57)
Summary · context
Randomized controlled trials (RCTs) comparing TZP at doses of 5, 10 and 15 mg in adults with type 2 diabetes were included.
Summary · context
Eight articles were included in this systematic review and meta-analysis.
Report a problemFND-3786088411

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:58 UTC
Study results updated
Version 1
9 Oct 2026, 03:07 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.